VRAXVirax Biolabs Group Ltd同业对比
Virax Biolabs Group Ltd 与In Vitro & In Vivo Diagnostic Substances的逐项对比:市值、估值、增长、盈利能力、质量与总回报,以及在同业组内的排名。所有数值均由引擎从 SEC 申报与延迟行情计算,排名仅为组内排序位置 —— 描述性数据,非投资建议。
完整同业对比
同业组:同 SIC 行业分类 (In Vitro & In Vivo Diagnostic Substances)| 公司 | 市值 | 市盈率(TTM) | 市净率 | 市销率 | 营收同比增长 | 净利同比增长 | 息税前利润率 | 净资产收益率 | 投入资本回报率 | 皮氏 F 值 | 一年总回报 | 股息率 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| VRAX本股 | $677685#11 | — | 0.1x#2 | 107.0x#10 | -96.0%#12 | 10.0%#10 | -97344.8%#12 | -106.4%#7 | — | — | -91.7%#12 | — |
| MYGN | $578M#2 | — | 1.9x#5 | 0.7x#1 | -1.6%#7 | -188.2%#13 | -47.0%#4 | -120.4%#8 | -76.1%#3 | — | -26.1%#4 | — |
| TKNO | $394M#3 | — | 6.3x#8 | 9.7x#6 | 7.4%#4 | 35.5%#4 | -41.9%#3 | -27.6%#2 | -25.2%#1 | 5#1 | 44.4%#2 | — |
| ICCC | $96M#5 | — | — | — | — | — | — | — | — | — | 69.5%#1 | — |
| IMDX | $90M#6 | — | — | 22.1x#8 | 115.6%#1 | 17.2%#8 | -1260.8%#9 | — | — | — | -55.2%#7 | — |
| BMRA | $8M#7 | — | 2.2x#6 | 1.8x#3 | -16.2%#9 | 24.1%#5 | -119.5%#6 | -103.5%#6 | — | — | -36.4%#5 | — |
| CDIO | $5M#8 | — | 0.6x#4 | 321.4x#11 | -57.5%#10 | 22.5%#6 | -43737.5%#10 | -87.5%#4 | — | — | -63.4%#8 | — |
| QCLS | $3M#9 | 0.0x#1 | 0.2x#3 | 2.2x#4 | -5.3%#8 | 50.2%#2 | -624.4%#7 | -72.3%#3 | -61.2%#2 | — | -87.4%#11 | — |
| VNRX | $3M#10 | — | — | 1.5x#2 | 40.0%#2 | 13.4%#9 | -1258.5%#8 | — | — | — | -97.8%#13 | — |
| CDIOW | $40249#12 | — | 0.0x#1 | 2.7x#5 | -57.5%#10 | 22.5%#6 | -43737.5%#10 | -87.5%#4 | — | — | -0.7%#3 | — |
| AWHL | — | — | — | — | 0.4%#6 | 2.4%#11 | -85.9%#5 | — | — | 3#2 | — | — |
| NNNN | $159M#4 | 24.8x#2 | 5.3x#7 | 18.4x#7 | 5.6%#5 | 169.9%#1 | 66.7%#1 | 21.2%#1 | — | — | -70.4%#9 | — |
| NYMXF | — | — | — | — | — | 49.2%#3 | — | — | — | — | -49.6%#6 | — |
| TRIB | $2.8B#1 | — | — | 45.6x#9 | 8.3%#3 | -32.4%#12 | -34.4%#2 | — | — | — | -75.0%#10 | 0.2%#1 |
数值来自 SEC 申报与延迟行情;排名仅为该组内的排序位置 —— 描述性数据,不构成评级或建议。 数据构建于 2026-11-04。
数据来自 SEC XBRL 申报与延迟行情 · 排名为组内排序 · 仅供参考 · 非投资建议